Annual EBITDA
-$117.65 M
-$32.42 M-38.04%
31 December 2023
Summary:
Cara Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$117.65 million, with the most recent change of -$32.42 million (-38.04%) on 31 December 2023. During the last 3 years, it has fallen by -$123.24 million (-2203.15%). CARA annual EBITDA is now -2203.15% below its all-time high of $5.59 million, reached on 31 December 2020.CARA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$10.44 M
+$7.59 M+42.08%
30 September 2024
Summary:
Cara Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$10.44 million, with the most recent change of +$7.59 million (+42.08%) on 30 September 2024. Over the past year, it has increased by +$17.53 million (+62.67%). CARA quarterly EBITDA is now -113.33% below its all-time high of $78.35 million, reached on 31 December 2020.CARA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$88.80 M
+$17.53 M+16.49%
30 September 2024
Summary:
Cara Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$88.80 million, with the most recent change of +$17.53 million (+16.49%) on 30 September 2024. Over the past year, it has increased by +$26.39 million (+22.91%). CARA TTM EBITDA is now -486.45% below its all-time high of $22.98 million, reached on 30 September 2021.CARA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CARA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.0% | +62.7% | +22.9% |
| 3 y3 years | -2203.2% | -883.3% | -486.4% |
| 5 y5 years | -52.8% | +69.6% | +14.2% |
CARA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -2203.2% | at low | -883.3% | +68.2% | -486.4% | +25.8% |
| 5 y | 5 years | -2203.2% | at low | -113.3% | +69.6% | -486.4% | +26.1% |
| alltime | all time | -2203.2% | at low | -113.3% | +69.6% | -486.4% | +26.1% |
Cara Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.44 M(-42.1%) | -$88.80 M(-16.5%) |
| June 2024 | - | -$18.03 M(-37.1%) | -$106.33 M(-11.2%) |
| Mar 2024 | - | -$28.67 M(-9.4%) | -$119.72 M(+1.8%) |
| Dec 2023 | -$117.65 M(+38.0%) | -$31.65 M(+13.1%) | -$117.65 M(+2.1%) |
| Sept 2023 | - | -$27.97 M(-11.0%) | -$115.18 M(+3.8%) |
| June 2023 | - | -$31.42 M(+18.1%) | -$111.00 M(+32.2%) |
| Mar 2023 | - | -$26.61 M(-8.8%) | -$83.98 M(-1.5%) |
| Dec 2022 | -$85.23 M(-3.4%) | -$29.18 M(+22.7%) | -$85.23 M(-4.1%) |
| Sept 2022 | - | -$23.78 M(+439.4%) | -$88.86 M(+34.4%) |
| June 2022 | - | -$4.41 M(-84.2%) | -$66.14 M(-28.5%) |
| Mar 2022 | - | -$27.85 M(-15.1%) | -$92.54 M(+4.9%) |
| Dec 2021 | -$88.19 M(-1676.6%) | -$32.82 M(+2990.2%) | -$88.19 M(-483.8%) |
| Sept 2021 | - | -$1.06 M(-96.6%) | $22.98 M(+225.0%) |
| June 2021 | - | -$30.82 M(+31.1%) | $7.07 M(-41.3%) |
| Mar 2021 | - | -$23.50 M(-130.0%) | $12.05 M(+115.4%) |
| Dec 2020 | $5.59 M(-105.0%) | $78.35 M(-561.7%) | $5.59 M(-105.4%) |
| Sept 2020 | - | -$16.97 M(-34.3%) | -$102.68 M(-14.5%) |
| June 2020 | - | -$25.84 M(-13.7%) | -$120.09 M(+1.5%) |
| Mar 2020 | - | -$29.95 M(+0.1%) | -$118.35 M(+6.2%) |
| Dec 2019 | -$111.48 M(+44.8%) | -$29.92 M(-13.0%) | -$111.48 M(+7.7%) |
| Sept 2019 | - | -$34.38 M(+42.7%) | -$103.48 M(+15.6%) |
| June 2019 | - | -$24.09 M(+4.4%) | -$89.49 M(+7.7%) |
| Mar 2019 | - | -$23.08 M(+5.3%) | -$83.10 M(+7.9%) |
| Dec 2018 | -$77.01 M | -$21.93 M(+7.5%) | -$77.01 M(+10.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$20.39 M(+15.2%) | -$69.53 M(+12.2%) |
| June 2018 | - | -$17.70 M(+4.1%) | -$61.98 M(+15.2%) |
| Mar 2018 | - | -$17.00 M(+17.7%) | -$53.79 M(-8.8%) |
| Dec 2017 | -$58.99 M(+3.6%) | -$14.45 M(+12.6%) | -$58.99 M(-11.6%) |
| Sept 2017 | - | -$12.83 M(+34.9%) | -$66.74 M(+1.8%) |
| June 2017 | - | -$9.51 M(-57.2%) | -$65.58 M(-4.8%) |
| Mar 2017 | - | -$22.20 M(+0.0%) | -$68.88 M(+21.0%) |
| Dec 2016 | -$56.94 M(+133.8%) | -$22.20 M(+90.1%) | -$56.94 M(+28.8%) |
| Sept 2016 | - | -$11.68 M(-8.8%) | -$44.21 M(+18.4%) |
| June 2016 | - | -$12.81 M(+24.9%) | -$37.35 M(+24.2%) |
| Mar 2016 | - | -$10.26 M(+8.3%) | -$30.08 M(+23.5%) |
| Dec 2015 | -$24.35 M(+40.8%) | -$9.47 M(+96.7%) | -$24.35 M(+28.0%) |
| Sept 2015 | - | -$4.82 M(-13.1%) | -$19.02 M(-7.7%) |
| June 2015 | - | -$5.54 M(+22.4%) | -$20.61 M(+10.9%) |
| Mar 2015 | - | -$4.53 M(+9.2%) | -$18.59 M(+7.5%) |
| Dec 2014 | -$17.29 M(-3232.1%) | -$4.14 M(-35.3%) | -$17.29 M(+14.8%) |
| Sept 2014 | - | -$6.41 M(+82.2%) | -$15.05 M(+25.5%) |
| June 2014 | - | -$3.52 M(+9.1%) | -$11.99 M(+781.8%) |
| Mar 2014 | - | -$3.22 M(+69.0%) | -$1.36 M(-346.4%) |
| Dec 2013 | $552.00 K(-110.6%) | -$1.91 M(-42.9%) | $552.00 K(-37.9%) |
| Sept 2013 | - | -$3.34 M(-147.0%) | $889.00 K(-79.0%) |
| June 2013 | - | $7.12 M(-642.4%) | $4.23 M(-246.8%) |
| Mar 2013 | - | -$1.31 M(-16.5%) | -$2.88 M(+83.5%) |
| Dec 2012 | -$5.21 M(-37.9%) | -$1.57 M | -$1.57 M |
| Dec 2011 | -$8.40 M | - | - |
FAQ
- What is Cara Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Cara Therapeutics?
- What is Cara Therapeutics annual EBITDA year-on-year change?
- What is Cara Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Cara Therapeutics?
- What is Cara Therapeutics quarterly EBITDA year-on-year change?
- What is Cara Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Cara Therapeutics?
- What is Cara Therapeutics TTM EBITDA year-on-year change?
What is Cara Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CARA is -$117.65 M
What is the all time high annual EBITDA for Cara Therapeutics?
Cara Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $5.59 M
What is Cara Therapeutics annual EBITDA year-on-year change?
Over the past year, CARA annual earnings before interest, taxes, depreciation & amortization has changed by -$32.42 M (-38.04%)
What is Cara Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CARA is -$10.44 M
What is the all time high quarterly EBITDA for Cara Therapeutics?
Cara Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $78.35 M
What is Cara Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CARA quarterly earnings before interest, taxes, depreciation & amortization has changed by +$17.53 M (+62.67%)
What is Cara Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CARA is -$88.80 M
What is the all time high TTM EBITDA for Cara Therapeutics?
Cara Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $22.98 M
What is Cara Therapeutics TTM EBITDA year-on-year change?
Over the past year, CARA TTM earnings before interest, taxes, depreciation & amortization has changed by +$26.39 M (+22.91%)